CERo Non Current Assets Total from 2010 to 2024
| CERO Stock | 0.07 0.01 8.42% |
Non Current Assets Total | First Reported 2010-12-31 | Previous Quarter 3.8 M | Current Value 3.7 M | Quarterly Volatility 72.4 M |
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
CERo |
Latest CERo Therapeutics' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of CERo Therapeutics Holdings, over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. CERo Therapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
CERo Non Current Assets Total Regression Statistics
| Arithmetic Mean | 143,758,600 | |
| Geometric Mean | 83,234,409 | |
| Coefficient Of Variation | 50.34 | |
| Mean Deviation | 55,933,654 | |
| Median | 178,717,134 | |
| Standard Deviation | 72,371,140 | |
| Sample Variance | 5237.6T | |
| Range | 175.1M | |
| R-Value | (0.69) | |
| Mean Square Error | 2919.9T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (11,238,885) | |
| Total Sum of Squares | 73326.1T |
CERo Non Current Assets Total History
About CERo Therapeutics Financial Statements
CERo Therapeutics investors utilize fundamental indicators, such as Non Current Assets Total, to predict how CERo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 3.8 M | 3.7 M |
Pair Trading with CERo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against CERo Stock
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.66 | LLY | Eli Lilly | PairCorr |
| 0.59 | VALN | Valneva SE ADR | PairCorr |
| 0.58 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.57 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings, to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of CERo Therapeutics Correlation against competitors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.